First Large-Scale Commercial Production Contract Secured... Full-Scale Operations Begin Next Year
Targeting Global CDMO Market by Linking Production Bases in Korea and the U.S.
Co-CEO Shin Yuyeol: "We Will Be a Partner That Works Alongside Customers"

Lotte Group Chairman Shin Dong-bin said on November 18, “I hope Lotte Biologics’ Plant 1 in Songdo, Incheon, will mark an important turning point that not only drives Lotte Group’s growth but also takes the competitiveness of Korea’s bio industry to a new level.”


Speaking at the completion ceremony for Lotte Biologics’ Plant 1 (Bio Campus) in Songdo, Yeonsu-gu, Incheon, Shin said, “The bio business is a future growth engine for Lotte Group and a next-generation industry that will lead Korea’s next generation.”


Shin Yuyeol, co-CEO of Lotte Biologics, also attended the ceremony. “The completion of the Songdo Bio Campus is meaningful not simply because it marks the completion of a new production facility, but because it lays the foundation for Lotte Biologics to help expand Korea’s large-scale biomanufacturing capacity,” he said. “We aspire to be a CDMO partner that works alongside customers over the long term, built on quality, technology and trust that customers can experience firsthand.”


Lotte Group Chairman Shin Dongbin (right) and Shin Yuyeol, co-CEO of Lotte Biologics and head of the Management Strategy Office at Lotte Holdings. Yonhap News Agency.

Lotte Group Chairman Shin Dongbin (right) and Shin Yuyeol, co-CEO of Lotte Biologics and head of the Management Strategy Office at Lotte Holdings. Yonhap News Agency.

View original image

120,000-Liter Production Base Secured... First Large-Scale Order Won


Lotte Biologics’ Songdo Plant 1 is a biopharmaceutical manufacturing facility whose construction began in March 2024 and which received approval for use in June 2026. The facility has a total floor area of approximately 99,558 square meters and a production capacity of 120,000 liters. Equipment qualification and validation are currently underway, with full-scale commercial production scheduled to begin in 2027.


In 2022, Lotte entered the contract development and manufacturing organization (CDMO) market by acquiring Bristol Myers Squibb’s Syracuse plant in the United States. It subsequently pursued a plan to invest approximately 4.6 trillion won in the Songdo Bio Campus, setting out to establish a domestic production base. By securing a large-scale production facility of its own in Korea after acquiring an existing U.S. facility, Lotte laid the groundwork for expanding its global business.


Lotte also secured initial production volumes ahead of the plant’s launch. On November 17, Lotte Biologics announced that it had signed its first large-scale biopharmaceutical manufacturing contract for Songdo Plant 1 with a global pharmaceutical company. The company did not disclose the client or the value of the contract, but securing a customer before commercial production is seen as laying the groundwork for future revenue.


Lotte Biologics Completes Songdo Plant 1; Shin Dong-bin: "Hope It Marks Turning Point in Boosting K-Bio Competitiveness" View original image

Lotte Biologics plans to target the global market with its “Dual Site” strategy, combining its commercial production experience in Syracuse, U.S., with Songdo’s large-scale production capacity. The company plans to build Songdo Plants 2 and 3 in succession, expanding total capacity, including that of its U.S. plant, to 400,000 liters.


Shin Yuyeol Attends Completion Ceremony Soon After Promotion, Signaling Strong Support for Bio Business


The event also drew attention as the first large-scale official event attended by third-generation owner Shin Yuyeol since his recent promotion to president in Lotte Group’s regular executive reshuffle. Since becoming co-CEO of Lotte Biologics last year, Shin has led major projects, including preparations for commercial production at the Songdo plant and efforts to secure more orders for the Syracuse campus in the United States. He has also attended global bio industry events in person, focusing on finding overseas customers and building partnerships.



Lotte Group cited the progress made in its bio business as one of the reasons for Shin’s promotion in this reshuffle. As head of the newly established Management Strategy Office at Lotte Holdings, Shin will also oversee the group’s mid- to long-term strategy and business portfolio adjustments. With the completion of the plant bringing the bio business into the full-scale commercialization phase, Shin and Lotte Biologics are expected to have a stronger presence within the group.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing